CDKN2A and neoplasm: Meanwhile, Driver at al. incorporated 15 targeted, high-risk molecular alterations (13 chromosomal alterations and loss of CDKN2A/B) with histologic (presence of frequent mitoses) and clinical (extent of resection, tumor volume, and recurrence status) factors to stratify meningioma.